SYNAPTIXBIO
SynaptixBio is developing lifesaving therapies for severe leukodystrophies. The company enables the translation of ground-breaking research in TUBB4a Leukodystrophy into a transformative therapy. Their updated news is imported into the website. The customer queries are addressed through an online form.
SYNAPTIXBIO
Industry:
Biotechnology Genetics Therapeutics
Founded:
2021-01-01
Address:
Oxford, Oxfordshire, United Kingdom
Country:
United Kingdom
Website Url:
http://www.synaptixbio.com
Total Employee:
1+
Status:
Active
Total Funding:
11.54 M GBP
Technology used in webpage:
Google Google Cloud Pound Sterling Wix
Similar Organizations
Beren Therapeutics
Beren Therapeutics is a biotechnology company that develops innovative therapies to make them accessible to every patient.
IntegraGen
IntegraGen is a biotechnology company developing molecular markers for central nervous system and metabolic diseases.
Ochre Bio
Ochre Bio is a biotechnology company that develops and builds a deep phenotyping platform to rejuvenate transplant livers.
ReViral
ReViral is a biotechnology company that develops and offers antiviral therapies for patients.
Current Employees Featured
Bent Jakobsen Founder & Board Member @ SynaptixBio
Founder & Board Member
2021-05-01
Dan Williams CEO, Executive Director and Co-founder @ SynaptixBio
CEO, Executive Director and Co-founder
2021-05-01
Michelle Teng Chief Scientific Officer, Founding Executive Director and Co-Founder @ SynaptixBio
Chief Scientific Officer, Founding Executive Director and Co-Founder
2021-05-01
Founder
Investors List
Innovate UK
Innovate UK investment in Grant - SynaptixBio
Official Site Inspections
http://www.synaptixbio.com
- Host name: unalocated.63.wixsite.com
- IP address: 185.230.63.107
- Location: Ashburn United States
- Latitude: 39.018
- Longitude: -77.539
- Metro Code: 511
- Timezone: America/New_York
- Postal: 20147
More informations about "SynaptixBio"
SynaptixBio - Crunchbase Company Profile & Funding
SynaptixBio may be growing as it has been awarded an Innovate UK grant, which is indicative of receiving financial support to further its research and development efforts. The grant is …See details»
SynaptixBio Ltd. - LinkedIn
SynaptixBio’s mission is to deliver gene therapies for fatal leukodystrophies in children caused by loss of function or mutation in a single gene. ... World Health Organization: 65 per 100,000 ...See details»
SynaptixBio | the team
SynaptixBio was founded in 2021 to enable translation of ground-breaking research in TUBB4a Leukodystrophy into a transformative therapy. Therapeutic development is based onto novel …See details»
SynaptixBio Company Profile 2024: Valuation, Funding …
SynaptixBio was founded in 2021. Where is SynaptixBio headquartered? SynaptixBio is headquartered in Oxford, United Kingdom. What is the size of SynaptixBio? SynaptixBio has 4 total employees. What industry is SynaptixBio …See details»
SYNAPTIXBIO LTD overview - Find and update company …
People for SYNAPTIXBIO LTD (13318389) More for SYNAPTIXBIO LTD (13318389) Registered office address 9400 Garsington Road, Oxford Business Park, Oxford, United Kingdom, OX4 …See details»
SynaptixBio - Funding, Financials, Valuation & Investors
SynaptixBio is a biotechnology research company that develops lifesaving therapies for severe leukodystrophies. Search Crunchbase. Start Free Trial . Chrome Extension. ... How much …See details»
SynaptixBio - Contacts, Employees, Board Members, Advisors
Organization. SynaptixBio . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. Highlights. Employee Profiles 3. About. SynaptixBio has …See details»
SynaptixBio Formed to Tackle One of the World’s Rarest Diseases
Oct 28, 2021 SynaptixBio was formed just a few weeks ago, in October 2021, in response to an unmet need. “I previously worked with Michelle Teng (also a co-founder of SynaptixBio), …See details»
SynaptixBio secures FDA designation to develop …
Feb 13, 2023 Oxford biotech firm SynaptixBio, which was founded to develop the world’s first treatment for a rare, incurable and deadly disease, has secured its first Food and Drug Administration designation.. SynaptixBio, which aims to …See details»
SynaptixBio Ltd gets FDA ODD for leukodystrophy
Mar 5, 2024 Using antisense oligonucleotides (ASO) to silence the beta tubulin 4a gene, Oxford-based SynaptixBio Ltd received its first ODD in early 2023 for a therapeutic that targets …See details»
New biotech firm launched to develop ‘revolutionary ... - SynaptixBio
Aug 17, 2021 SynaptixBio also has an option to exclusively license CHOP research related to this project. Antisense Oligonucleotides (ASOs) therapy, which has previously been used to …See details»
SynaptixBio enters into a pioneering new licence agreement in bid …
SynaptixBio – the Oxford-based biotech firm on a mission to develop the first treatment for a rare, incurable and deadly disease – has entered into a license agreement regarding the condition …See details»
SynaptixBio awarded second FDA Orphan Drug Designation to …
Apr 30, 2024 Orphan Drug Designation. SynaptixBio is using antisense oligonucleotide (ASO) technology to tackle TUBB4A-related leukodystrophies; ASOs can alter the expression of …See details»
SynaptixBio and Evotec extend rare disease therapies partnership
Jul 24, 2024 SynaptixBio and Evotec have announced they are extending their partnership to find further candidate drugs to treat H-ABC, the most severe form of TUBB4A leukodystrophy. …See details»
Synaptixbio sets off on quest to find therapy for rare CNS disease
Oct 15, 2021 U.K.’s Synaptixbio Ltd. has launched, aiming to tackle a rare and often fatal disease of the central nervous system (CNS), TUBB4a leukodystrophy. It’s a disease that was …See details»
SynaptixBio Readying to Take First Antisense Oligonucleotide …
Jul 31, 2024 Oxford-based SynaptixBio is a "virtual company" focused solely on rare leukodystrophies for the foreseeable future, according to CEO and Cofounder Dan Williams. ...See details»
news - SynaptixBio
News and press releases about SynaptixBio. SynaptixBio was founded in 2021 to enable the translation of ground-breaking research in TUBB4a Leukodystrophy into a transformative …See details»
SynaptixBio Ltd and Evotec SE expand collaboration
Jul 23, 2024 At the end of July, SynaptixBio announced its collaboration with drug discovery specialist Evotec SE, which began in April 2022, for the purpose of expanding the pipeline with …See details»
the science - SynaptixBio
SynaptixBio is a rare disease biotech pioneering ground-breaking development for treatment of severe leukodystrophies. Leukodystrophies affect the brain and manifest with a spectrum of …See details»